Dash Bio Raises $6.5M in Seed Funding to Revolutionize Drug Development with AI and Robotics
Dash Bio is focused on building cutting-edge solutions for the drug development process.
Company Name: Dash Bio
Location: Newton, MA
Sector: Tech-Enabled Drug Development Services
Funding Details: Raised $6.5M in Seed funding, led by Freestyle Capital with participation from Swift Ventures, LifeX Ventures, and other private investors.
Leadership: Founded by Dave Johnson (CEO), Ander Tallett (COO), and Ely Porter.
Purpose of Investment:
- Expand operations.
- Enhance development efforts as the company builds out new capabilities in drug development.
Product and Innovation:
Dash Bio adopts a technology-first approach to reinventing the drug development lifecycle. By integrating AI, robotics, and fully automated software systems, the company is creating innovative solutions to streamline the process of bringing drugs to market. Their first capability is a highly automated clinical bioanalysis lab that provides GLP-compliant services.
About the Company:
Dash Bio is focused on building cutting-edge solutions for the drug development process. The company aims to deliver more efficient and reliable services to the pharmaceutical industry, leveraging automation to drive innovation.
